Treatment of hairy cell leukemia with cladribine (2-chlorodeoxyadenosine) by subcutaneous bolus injection: A phase II study

Annals of Oncology

Volumn 13, Issue 10, 2002, Pages 1641-1649

  von Rohr, A ^a   Schmitz, S F H ^b   Tichelli, A ^c   Hess, U ^d   Piguet, D ^e   Wernli, M ^f   Frickhofen, N ^g   Konwalinka, G ^h   Zulian, G ⁱ   Ghielmini, M ^j   Rufener, B ^b   Racine, C ^a   Fey, M F ^a   Cerny, T ^a   Betticher, D ^a   Tobler, A ^a  

^a UNIVERSITY OF BERN   (Switzerland)

^b SIAK Coordinating Center   (Switzerland)

^c UNIVERSITY HOSPITAL BASEL   (Switzerland)

^d CANTONAL HOSPITAL ST GALLEN   (Switzerland)

^e Hopital Pourtales Neuchatelois   (Switzerland)

^f CANTONAL HOSPITAL AARAU   (Switzerland)

^g UNIVERSITY HOSPITAL ULM   (Germany)

^h INNSBRUCK MEDICAL UNIVERSITY   (Austria)

ⁱ UNIVERSITY HOSPITAL   (Switzerland)

^j ONCOLOGY INSTITUTE OF SOUTHERN SWITZERLAND   (Switzerland)

more..

Author keywords

2 Chlorodeoxyadenosine; Cladribine; Hairy cell leukemia

Indexed keywords

ALLOPURINOL; ALPHA INTERFERON; ANTIBIOTIC AGENT; ANTINEOPLASTIC AGENT; CLADRIBINE;

ARTICLE; BOLUS INJECTION; CANCER RECURRENCE; CAREGIVER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE COURSE; DRUG RESPONSE; FEMALE; HAIRY CELL LEUKEMIA; HUMAN; HYPERURICEMIA; LEUKOPENIA; LYMPHOCYTE COUNT; LYMPHOCYTE SUBPOPULATION; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; MALE; OPPORTUNISTIC INFECTION; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SPLENECTOMY; TREATMENT FAILURE;

ADULT; AGED; ANTINEOPLASTIC AGENTS; CLADRIBINE; DISEASE PROGRESSION; FEMALE; HUMANS; INJECTIONS, SUBCUTANEOUS; LEUKEMIA, HAIRY CELL; LEUKOPENIA; MALE; MIDDLE AGED; RECURRENCE; SURVIVAL;

EID: 0036809024     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/annonc/mdf272     Document Type: Article

References (53)

1. Flandrin G, Sigaux F, Sebahoun G, Bouffette P. Hairy cell leukemia: clinical presentation and follow-up of 211 patients. Semin Oncol 1984; 11 (Suppl. 2): 458-471.
2. Golomb HM, Catovsky D, Golde DW. Hairy cell leukemia: a clinical review based on 71 cases. Ann Intern Med 1978; 89: 677-683.
3. Yam LT, Janckila AJ, Li CY, Lam WK. Cytochemistry of tartrate-resistant acid phosphatase: 15 years' experience. Leukemia 1987; 1: 285-288.
4. Anderson KC, Boyd AW, Fisher DC et al. Hairy cell leukemia: a tumor of pre-plasma cells. Blood 1985; 65: 620-629.
5. Yam LT, Phyliky RL, Li CY. Benign and neoplastic disorders simulating hairy cell leukemia. Semin Oncol 1984; 11: 353-361.
6. Westbrook CA, Groopman JE, Golde DW. Hairy cell leukemia: disease pattern and prognosis. Cancer 1984; 54: 500-506.
7. Paoletti M, Bitter MA, Vardiman JW. Hairy cell leukemia: morphologic, cytochemical, and immunologic features. Clin Lab Med 1988; 8: 179-195.
8. Cawley JC, Burns GF, Hayhoe FGJ. A chronic lymphoproliferative disorder with distinctive features: a distinct variant of hairy-cell leukemia. Leuk Res 1980; 4: 547-559.
9. Catovsky D, O'Brien M, Melo JV et al. Hairy cell leukemia (HCL) variant: an intermediate disease between HCL and B prolymphocytic leukemia. Semin Oncol 1984; 11: 362-369.
10. Sainati L, Matutes E, Mulligan S et al. A variant form of hairy cell leukemia resistant to α-interferon: clinical and phenotypic characteristics of 17 patients. Blood 1990; 76: 157-162.
11. Dunphy CH, Petruska PJ. Atypical prolymphocytic variant of hairy-cell leukemia: case report and review of the literature. Am J Hematol 1996; 53: 121-125.
12. Berman E, Heller G, Kempin S et al. Incidence of response and long-term follow-up in patients with hairy cell leukemia treated with recombinant interferon alfa-2a. Blood 1990; 75: 839-845.
13. Golomb HM, Fefer A, Golde DW et al. Sequential evaluation of alpha-2b-interferon treatment in 128 patients with hairy cell leukemia. Semin Oncol 1987; 14 (Suppl 2): 13-17.
14. Ratain MJ, Golomb HM, Vardiman JW et al. Relapse after interferon alfa-2b therapy for hairy-cell leukemia: analysis of prognostic variables. J Clin Oncol 1988; 6: 1714-1721.
15. Spiers AS, Moore D, Cassileth PA et al. Remissions in hairy-cell leukemia with pentostatin (2′-deoxycoformycin). N Engl J Med 1987; 316: 825-830.
16. Kraut EH, Bouroncle BA, Grever MR. Pentostatin in the treatment of advanced hairy cell leukemia. J Clin Oncol 1989; 7: 168-172.
17. Grem JL, King SA, Cheson BD et al. Pentostatin in hairy cell leukemia: treatment by the special exception mechanism. J Natl Cancer Inst 1989; 81: 448-453.
18. Johnston JB, Eisenhauer E, Corbett WE et al. Efficacy of 2′-deoxycoformycin in hairy-cell leukemia: a study of the National Cancer Institute of Canada Clinical Trials Group. J Natl Cancer Inst 1988; 80: 765-769.
19. Saven A, Piro LD. Treatment of hairy cell leukemia. Blood 1992; 79: 1111-1120.
20. Piro LD, Carrera CJ, Carson DA, Beutler E. Lasting remissions in hairy-cell leukemia induced by a single infusion of 2-chlorodeoxyadenosine. N Engl J Med 1990; 322: 1117-1121.
21. Piro LD, Saven A, Ellison D et al. Prolonged complete remissions following 2-chlorodeoxyadenosine (2-CdA) in hairy cell leukemia (HCL). Proc Am Soc Clin Oncol 1992; 11: 259 (Abstr 846).
22. Estey EH, Kurzrock R, Kantarjian HM et al. Treatment of hairy cell leukemia with 2-chlorodeoxyadenosine (2-CdA). Blood 1992; 79: 882-887.
23. Juliusson G, Liliemark J. Rapid recovery from cytopenia in hairy cell leukemia after treatment with 2-chloro-2′-deoxyadenosine (CdA): relation to opportunistic infections. Blood 1992; 79: 888-894.
24. Tallman MS, Hakimian D, Variakojis D et al. A single cycle of 2-chlorodeoxyadenosine results in complete remission in the majority of patients with hairy cell leukemia. Blood 1992; 80: 2203-2209.
25. Hoffman M, Rai KR, Janson D et al. Comparison of complete remission (CR) rates among previously treated or untreated hairy cell leukemia (HCL) patients (pts) with 2-chlorodeoxyadenosine (CdA). Proc Am Soc Clin Oncol 1992; 11: 271 (Abstr 895).
26. Lauria F, Benfenati D, Zinzani PL et al. 2-chlorodeoxyadenosine in the treatment of hairy cell leukemia patients relapsed after α-IFN. Blood 1991; 78 (Suppl 1): 34a (Abstr 128).
27. Cladribin Product Monograph.
28. Robak T, Blasinska-Morawiec M, Blonski J et al. 2-chlorodeoxyadenosine (cladribine) in the treatment of hairy cell leukemia and hairy cell leukemia variant: 7-year experience in Poland. Eur J Haematol 1999; 62: 49-56.
29. Sonderegger TA, Betticher DC, Egger T et al. 2-Chlorodeoxyadenosine (2-CDA), pharmacokinetic comparison of continuous intravenous (iv) and subcutaneous bolus (sc) application. VI International Conference on Malignant Lymphoma. Lugano, Switzerland, 1996.
30. Liliemark J, Albertioni F, Hassan M, Juliusson G. On the bioavailability of oral and subcutaneous 2-chloro-2′-deoxyadenosine in humans: alternative routes of administration. J Clin Oncol 1992; 10: 1514-1518.
31. Liliemark J, Juliusson G. Cellular pharmacokinetics of 2-chloro-2′ deoxyadenosine nucleotides: comparison of intermittent and continuous intravenous infusion and subcutaneous and oral administration in leukemia patients. Clin Cancer Res 1995; 1: 385-390.
32. Juliusson G, Liliemark J, Hippe E et al. Subcutaneous injections of 2-chloro-2′-deoxyadenosine (CdA) as treatment for symptomatic hairy cell leukemia (HCL). Blood 1992; 80 (Suppl 1): 359a (Abstr 1427).
33. Anonymous. Consensus resolution: Proposed criteria for evaluation of response to treatment in hairy cell leukemia. Leukemia 1987; 1: 405.
34. Simon R. Optimal two-stage designs for phase II clinical trials. Control Clin Trials 1989; 10: 1-10.
35. Cox DR, Snell EJ. Analysis of Binary Data, 2nd edition. London: Chapman and Hall 1988.
36. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-481.
37. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 1966; 50: 163-167.
38. Cox DR. Regression models and life tables. J R Stat Soc B 1972; 34: 187-220.
39. Marubini E, Valsecchi MG. Analysing Survival Data from Clinical Trials and Observation Studies. Chichester: Wiley and Sons 1995.
40. Juliusson G, Heldal D, Hippe E et al. Subcutaneous injections of 2-chlorodeoxyadenosine for symptomatic hairy cell leukemia. J Clin Oncol 1995; 13: 989-995.
41. Tallman MS, Hakimian D, Rademaker AW et al. Relapse of hairy cell leukemia after 2-chlorodeoxyadenosine: long-term follow-up of the Northwestern University experience. Blood 1996; 88: 1954-1959.
42. Hoffman MA, Janson D, Rose E, Rai KR. Treatment of hairy cell leukemia with cladribine: response, toxicity, and long-term follow-up. J Clin Oncol 1997; 15: 1138-1142.
43. Saven A, Burian C, Koziol JA, Piro LD. Long-term follow-up of patients with hairy cell leukemia after cladribine treatment. Blood 1998; 92: 1918-1926.
44. Cheson BD, Sorensen JM, Vena DA et al. Treatment of hairy cell leukemia with 2-chlorodeoxyadenosine via the group C protocol mechanism of the National Cancer Institute: a report of 979 patients. J Clin Oncol 1998; 16: 3007-3015.
45. + lymphocyte counts in patients with hairy cell leukemia. Blood 1994; 83: 2906-2911.
46. Mercieca J, Matutes E, Emmett E et al. 2-Chlorodeoxyadenosine in the treatment of hairy cell leukaemia: differences in response in patients with and without abdominal lymphadenopathy. Br J Haematol 1996; 93: 409-411.
47. Lauria F, Rondelli D, Raspadori D et al. Rapid restoration of natural killer activity following treatment with 2-chlorodeoxyadenosine in 22 patients with hairy-cell leukemia. Eur J Haematol 1994; 52: 16-20.
48. Juliusson G, Lenkei R, Liliemark J. Flow cytometry of blood and bone marrow cells from patients with hairy cell leukemia: Phenotype of hairy cells and lymphocyte subsets after treatment with 2-chlorodeoxyadenosine. Blood 1994; 83: 3672-3681.
49. Kurzrock R, Strom SS, Estey E et al. Second cancer risk in hairy cell leukemia: Analysis of 350 patients. J Clin Oncol 1997; 15: 1803-1810.
50. Au WY, Klasa RJ, Gallagher R et al. Second malignancies in patients with hairy cell leukemia in British Columbia: A 20-year experience. Blood 1998; 92: 1160-1164.
51. Cheson BD, Vena DA, Barrett J, Freidlin B. Second malignancies as a consequence of nucleoside analog therapy for chronic lymphoid leukemias. J Clin Oncol 1999; 17: 2454-2460.
52. Kampmeier P, Spielberger R, Dickstein J et al. Increased incidence of second neoplasms in patients treated with interferon α-2b. Blood 1994; 83: 2931-2936.
53. Saven A, Cheung WK, Smith I et al. Pharmacokinetic study of oral and bolus intravenous 2-chlorodeoxyadenosine in patients with malignancy. J Clin Oncol 1996; 14: 978-983.